$ADXS Receives #FDA #FastTrack Designation as #Adjuvant in #Cervical #Cancer

PRINCETON, N.J., July 21, 2016  — Advaxis, Inc. (NASDAQ:ADXS), a clinical stage biotechnology company developing cancer immunotherapies, today announced that the U.S. Food and Drug Administration (FDA) has designated the Company’s lead immunotherapy candidate, axalimogene filolisbac (AXAL), as a Fast Track product for adjuvant therapy for high-risk locally advanced cervical cancer patients. The investigation of AXAL in this under-served population will be conducted in accordance with the Special Protocol Assessment (SPA) recently granted by the FDA.

“This Fast Track designation for AXAL comes on the heels of the SPA agreement and underscores the collaborative efforts of Advaxis and the FDA in expediting a medically significant clinical program.  This designation brings us one step closer to achieving our goal with the AIM2CERV trial, which aims to extend disease free survival for this serious and life-threatening condition and prevent disease recurrence,” said Daniel J. O’Connor, President and Chief Executive Officer of Advaxis.

In 2014, AXAL was granted FDA Orphan Drug designation for the treatment of invasive cervical cancer.

AXAL is a targeted immunotherapy which attacks human papillomavirus (HPV)-associated cancers by altering a live strain of Listeria monocytogenes (Lm) bacteria to generate cancer fighting T cells directed against the specific cancer antigen and neutralizing factors that protect the tumor microenvironment from immunologic attack and contribute to tumor growth.

The FDA established the Fast Track Drug Development Program under the FDA Modernization Act of 1997. The program is designed to facilitate the development and expedite the review of therapies intended to treat serious or life-threatening conditions and that demonstrate the potential to address unmet medical needs. The advantages of Fast Track designation include actions to help expedite development, including opportunities for frequent interactions with the FDA to discuss all aspects of development to support approval, eligibility for priority review at the time of Biologics License Application (BLA) submission and early review of portions of the application before submitting a complete application.

About Cervical Cancer

Cervical cancer is the fourth most common cancer in women worldwide. In the United States, nearly 13,000 new cases are diagnosed, and approximately 4,100 deaths are reported because of cervical cancer. According to the WHO/ICO Information Centre on HPV and Cervical Cancer, about 3.9 percent of women in the U.S. are estimated to harbor high-risk cervical HPV infection at a given time, and 71.7 percent of invasive cervical cancers are attributed to high-risk HPV strains.

About Axalimogene Filolisbac

Axalimogene filolisbac (AXAL) is Advaxis’ lead Lm Technology™ immunotherapy candidate for the treatment of HPV-associated cancers and is in clinical trials for three potential indications: invasive cervical cancer, head and neck cancer, and anal cancer. In a completed randomized Phase 2 study in recurrent/refractory cervical cancer, AXAL showed apparent prolonged survival, objective tumor responses, and a manageable safety profile alone or in combination with chemotherapy, supporting further development of the Company’s Lm Technology™. AXAL has Orphan Drug Designation in the U.S. for the treatment of anal cancer.

About Advaxis, Inc.

Advaxis, Inc. is a clinical-stage biotechnology company developing multiple cancer immunotherapies based on its proprietary Lm Technology™. The Lm Technology™, using bioengineered live attenuated Listeria monocytogenes (Lm) bacteria, is the only known cancer immunotherapy agent shown in preclinical studies to both generate cancer fighting T cells directed against cancer antigens and neutralize Tregs and myeloid-derived suppressor cells (MDSCs) that protect the tumor microenvironment from immunologic attack and contribute to tumor growth. Advaxis’ lead Lm Technology™ immunotherapy, axalimogene filolisbac, targets human papillomavirus (HPV)-associated cancers and is in clinical trials for three potential indications: Phase 2 in invasive cervical cancer, Phase 1/2 in head and neck cancer, and Phase 1/2 in anal cancer. The U.S. Food and Drug Administration (FDA) has granted axalimogene filolisbac orphan drug designation for each of these three clinical settings. Advaxis has two additional immunotherapy products: ADXS-PSA in prostate cancer and ADXS-HER2 in HER2 expressing solid tumors, in human clinical development.

For additional information on Advaxis, visit www.advaxis.com and connect on Twitter, LinkedIn, Facebook, YouTube and Google+.

Advaxis Forward-Looking Statement

This media statement contains forward-looking statements, including, but not limited to: statements regarding Advaxis’ ability to develop the next generation of cancer immunotherapies; and the safety and efficacy of Advaxis’ proprietary immunotherapies. These forward-looking statements are subject to a number of risks, including the risk factors set forth from time to time in Advaxis’ SEC filings, including but not limited to its report on Form 10-K for the fiscal year ended October 31, 2015, which is available at http://www.sec.gov. Advaxis undertakes no obligation to publicly release the result of any revision to these forward-looking statements, which may be made to reflect the events or circumstances after the date hereof or to reflect the occurrence of unanticipated events, except as required by law. You are cautioned not to place undue reliance on any forward-looking statements.

CONTACTS:
           
Company:
Advaxis, Inc.
Greg Mayes, Executive Vice President and COO
mayes@advaxis.com
609.250.7515

Media Contact:
JPA Health Communications
Nic DiBella
nic@jpa.com
617.945.5183

$BVX Announces #Sales Channel #Partnership Agreement with #Hologic for #JPlasma®

Bovie Medical (NYSE MKT:BVX), announced a sales channel partnership agreement with Hologic, effective immediately.

Hologic will add Bovie’s J-Plasma® product line to its world class portfolio of healthcare solutions in gynecological and gynecological/oncological surgery in three U.S. regions.

The initial six-month agreement provides certain members of Hologic’s direct GYN Surgical sales force with access to J-Plasma® and includes the option to extend the agreement into a worldwide distribution pact that would involve Hologic’s entire surgical sales force.

Bovie Medical’s CEO, Robert L. Gershon noted, “We are proud to partner with a Company of Hologic’s caliber. This agreement is an important milestone in our strategy to scale J-Plasma® through select sales channel partnerships across multiple specialties that represent large addressable market opportunities.”

Commenting on the agreement, Thomas P. O’Neill, Hologic Division President, GYN Surgical Solutions said, “J-Plasma®’s reputation for unparalleled precision and safety makes it an ideal product for surgical procedures involving delicate surrounding tissue and structures. This agreement aligns with our strategy of providing our customers with cutting-edge technology that makes a real difference in patients’ lives.”

About Bovie Medical Corporation

Bovie Medical Corporation is a leading maker of medical devices and supplies as well as the developer of J-Plasma®, a patented new plasma-based surgical product for cutting and coagulation. J-Plasma® utilizes a helium ionization process to produce a stable, focused beam of ionized gas that provides surgeons with greater precision, minimal invasiveness and an absence of conductive currents through the patient during surgery. Bovie Medical Corporation is also a leader in the manufacture of a range of electrosurgical products and technologies, marketed through both private labels and the Company’s own well-respected brands (Bovie®, Aaron®, IDS™ and ICON™) to distributors worldwide. The Company also leverages its expertise through original equipment manufacturing (OEM) agreements with other medical device manufacturers. For further information about the Company’s current and new products, please refer to the Investor Relations section of Bovie Medical Corporation’s www.boviemed.com.

Investor Relations:
MBS Value Partners
Hugh Collins, 212-223-4632
investor.relations@boviemed.com

$MTBC Q2 FY16 #FinancialResults: August 11, 2016

$EYES Q2 FY16 #FinancialResults – July 28, 2016 #ConferenceCall

Second Sight Medical Products, Inc. (NASDAQ:EYES), a developer, manufacturer and marketer of implantable visual prosthetics to provide some useful vision to blind patients, will release its second quarter 2016 financial results on Thursday, July 28, 2016, after the close of the U.S. financial markets.

Dr. Robert Greenberg, Chairman, Will McGuire, President and Chief Executive Officer, and Tom Miller, Chief Financial Officer, will host a conference call to discuss the results as follows:

A replay of the conference call will be available for two weeks after the call’s completion by dialing (800) 633-8284 (U.S.) or (402) 977-9140 (International). The conference ID for the replay is 21815294. The archived webcast will be available for 30 days via the aforementioned URL.

About the Argus II® Retinal Prosthesis System

Second Sight’s Argus II System provides electrical stimulation that bypasses the defunct retinal cells and stimulates remaining viable cells inducing visual perception in individuals with severe to profound Retinitis Pigmentosa. The Argus II works by converting images captured by a miniature video camera mounted on the patient’s glasses into a series of small electrical pulses, which are transmitted wirelessly to an array of electrodes implanted on the surface of the retina. These pulses are intended to stimulate the retina’s remaining cells, resulting in the perception of patterns of light in the brain. The patient then learns to interpret these visual patterns, thereby regaining some visual function. The Argus II is the first artificial retina to receive widespread approval, and is offered at approved centers in Canada, France, Germany, Italy, Netherlands, Saudi Arabia, Spain, Switzerland, Turkey, United Kingdom, and the U.S.

About Second Sight

Second Sight’s mission is to develop, manufacture and market innovative implantable visual prosthetics to enable blind individuals to achieve greater independence. Second Sight has developed and now manufactures and markets the Argus® II Retinal Prosthesis System. Enrollment has been completed in a feasibility trial to test the safety and utility of the Argus II in individuals with Dry Age-Related Macular Degeneration. Second Sight is also developing the Orion™ I Visual Cortical Prosthesis to restore some vision to individuals who are blind due to causes other than preventable or treatable conditions. U.S. Headquarters are in Sylmar, California, and European Headquarters are in Lausanne, Switzerland. For more information, visit www.secondsight.com.

Investor Relations:
Institutional Investors
In-Site Communications, Inc.
Lisa Wilson, President
212-452-2793
lwilson@insitecony.com
or
Individual Investors
MZ North America
Greg Falesnik, Senior Vice President
949-385-6449
greg.falensik@mzgroup.us

$ABUS #Topline Results from #TKMPLK1 #HepatocellularCarcinoma #ClinicalTrial

Promising Anti-Tumor Activity Observed
Arbutus to Explore Partnership Options to Enable Further Study

VANCOUVER, B.C. and DOYLESTOWN, Pa., July 19, 2016 — Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading hepatitis B virus (HBV) therapeutic solutions company, today reported topline results from the completed Phase I/II TKM-PLK1 clinical study in patients with advanced Hepatocellular Carcinoma (HCC). Arbutus intends to explore partnership opportunities to enable further study of TKM-PLK-1 in HCC.

Arbutus today reported the following topline results from the Phase I/II study of TKM-PLK1 in HCC:

• TKM-PLK1 was well-tolerated at all dose levels;
• 51% of subjects showed overall stable disease (SD) according to RECIST criteria;
• 22% of subjects showed an overall partial response (PR) according to Choi response criteria;
• Tumor density reduction of up to 59% was observed;

“We are encouraged by the results from the TKM-PLK1 clinical trial in HCC patients and believe it supports further evaluation of this candidate as a potential treatment for HCC,” said Dr. Mark Kowalski, Arbutus’ Chief Medical Officer. “The observed radiographic tumor density changes are consistent with tumor necrosis in a significant proportion of subjects, warranting further study of TKM-PLK1 for HCC, alone and in combination with other therapies.”

“We are very pleased to report the positive results of this study of TKM-PLK1 in HCC, which we view as further validation of our capability to develop promising product candidates using our proprietary LNP delivery technology,” said Dr. Mark J. Murray, Arbutus’ President and CEO. “Given Arbutus’ focus on HBV, we look forward to finding the right partner to advance the development of TKM-PLK1 for HCC and maximize the value of this asset for our shareholders.”

Trial Design
The Phase I/II TKM-PLK1 HCC clinical study was an open-label, multi-center, study in patients with advanced HCC conducted in the US, Asia, and Canada. The trial was designed to assess the safety, tolerability, pharmacokinetics, and preliminary efficacy of the product. TKM-PLK1 was administered weekly with each four-week cycle consisting of three once-weekly doses followed by a rest week. The study included a total of 43 subjects (12 subjects in the dose escalation arm, followed by 31 subjects in the expansion cohort). The HCC efficacy endpoint of the study was tumor response rate.

About TKM-PLK1
TKM-PLK1 (TKM-080301) is a lipid nanoparticle (LNP) encapsulated small interfering RNA (siRNA) directed against polo-like kinase 1 (PLK1), a protein involved in tumor cell proliferation and a validated oncology target. Inhibition of PLK1 expression prevents the tumor cell from completing cell division, resulting in cell cycle arrest and death of the cancer cell. TKM-PLK1 has been evaluated in clinical trials with patients who have HCC, gastrointestinal neuroendocrine tumors (GI-NET), and adrenocortical carcinoma (ACC).

About Arbutus
Arbutus Biopharma Corporation is a biopharmaceutical company dedicated to discovering, developing and commercializing a cure for patients suffering from chronic HBV infection.  Arbutus is headquartered in Vancouver, BC, Canada with offices in Doylestown, PA, USA. For more information, visit www.arbutusbio.com.

Forward Looking Statements and Information
This press release contains forward-looking statements within the meaning of the Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and forward looking information within the meaning of Canadian securities laws (collectively, “forward-looking statements”). Forward-looking statements in this press release include statements about exploring partnership opportunities to enable further study of TKM-PLK-1 in HCC.

With respect to the forward-looking statements contained in this press release, Arbutus has made numerous assumptions regarding, among other things: the effectiveness and timeliness of preclinical and clinical trials, and the usefulness of the data; the continued demand for Arbutus’ assets; and the stability of economic and market conditions. While Arbutus considers these assumptions to be reasonable, these assumptions are inherently subject to significant business, economic, competitive, market and social uncertainties and contingencies.

Additionally, there are known and unknown risk factors which could cause Arbutus’ actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements contained herein. Known risk factors include, among others: anticipated pre-clinical and clinical trials may be more costly or take longer to complete than anticipated, and may never be initiated or completed, or may not generate results that warrant future development of the tested drug candidate; Arbutus may not receive the necessary regulatory approvals for the clinical development of Arbutus’ products; economic and market conditions may worsen; and market shifts may require a change in strategic focus.

A more complete discussion of the risks and uncertainties facing Arbutus appears in Arbutus’ Annual Report on Form 10-K and Arbutus’ continuous disclosure filings, which are available at www.sedar.com and at www.sec.gov. All forward-looking statements herein are qualified in their entirety by this cautionary statement, and Arbutus disclaims any obligation to revise or update any such forward-looking statements or to publicly announce the result of any revisions to any of the forward-looking statements contained herein to reflect future results, events or developments, except as required by law.

Contact Information 
Investors
Adam Cutler
Senior Vice President, Corporate Affairs
Phone: 604.419.3200 
Email: acutler@arbutusbio.com

Helia Baradarani
Senior Manager, Investor Relations
Phone: 604.419.3200
Email: hbaradarani@arbutusbio.com

Media
Please direct all media inquiries to: media@arbutusbio.com

$DRIO Reports 100%-Plus Monthly #Growth in #US Users Since Launch

Direct-to-Consumer Digital Marketing Strategy Driving Rapid Initial Market Penetration

BOSTON, July 19, 2016

LabStyle Innovations (NASDAQ: DRIO) – a leader in digital health and mobile health solutions and the developer of the Dario™ Smart Diabetes Management Solution – today announced that since the U.S. soft launch in March, the Company has seen rapid market penetration, including better than 100% growth per month in users during the second quarter.

Initial results:

– More than 4,550 Dario All-in-one Smart Glucose Meter Devices were purchased by U.S. customers by June 30, 2016

– At June end, the Company had more than 4,900 U.S. users registered on its servers

– This traction initiated by a soft launch has ramped during the second quarter, as 3,000 of the devices were purchased in June alone, representing 200% growth over the soft launch period initiated at the second half of March, 2016 in the U.S.

LabStyle Innovations established a direct-to-consumer business model in the U.S. to achieve a higher and faster penetration rate into this market during the launch phase. This model has been applied by a digital marketing strategy.  The combination of an innovative and highly engaging product with an attractive business model that allows users join Dario as subscribers with attractive pricing, makes the direct to consumer digital channel very successful. The Company has invested in a robust digital marketing department with in-house platforms, experienced personnel and robust infrastructures to support expected growth of users and online subscribers in this market. The current efforts are focused on expanding its digital traffic sources in order to widen its online presence and exposure to potential customers moving forward to achieve a higher rate of user acquisition to support the Company’s revenue goals.

“The initial results of our direct-to-consumer launch in the U.S. are encouraging and demonstrate the demand for our innovative, consumer-focused, technology based solution,“ said Erez Raphael, LabStyle Innovations Chairman & CEO, “Our digital marketing strategy  has been very effective in these first few months and along with our superior device accuracy, robust mobile data management solutions and unique business model, I am confident we are building a strong platform that will scale up and disrupt the multi-billion dollar diabetes monitoring industry.“

LabStyle Innovations’ flagship product, The Dario™ Smart Diabetes Management Solution, is a platform for diabetes management that combines an all-in-one blood glucose meter and a robust, real-time native smartphone app that includes a wide variety of tools to support and engage users living with diabetes, their doctors and the healthcare system.

About LabStyle Innovations

LabStyle Innovations is a leader in digital health self-management solutions. LabStyle Innovations delivers the ability to combine and analyze consumer health data to personalize treatment and advance medical knowledge. The Dario™ Smart Diabetes Management Solution is a platform for diabetes management that combines an all-in-one blood glucose meter, native smart phone app, website portal and a wide variety of treatment tools to support more proactive and better informed decisions by users living with diabetes, their doctors and healthcare systems.  Having recently launched in the largest market in the world for glucose monitoring, U.S. sales are expected to have a significant impact on revenues and gross margins. With marketing clearance in Europe and the U.S., the Dario iOS mobile app recently launched with reimbursement in the United Kingdom, Australia, Israel, Italy, and Canada, and has also launched in New Zealand, Netherlands, Italy, and Belgium.  For more information, visit http://mydario.investorroom.com/

Cautionary Note Regarding Forward-Looking Statements

This news release and the statements of representatives and partners of LabStyle Innovations (the “Company”) related thereto contain or may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as “plan,” “project,” “potential,” “seek,” “may,” “will,” “expect,” “believe,” “anticipate,” “intend,” “could,” “estimate” or “continue” are intended to identify forward-looking statements.  For example, when the Company describes its growth strategy, says that it will disrupt the diabetes monitoring industry, and says that it expects U.S. sales to have a significant impact on revenues and gross margins, it is using forward-looking statements. Readers are cautioned that certain important factors may affect the Company’s actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release. Factors that may affect the Company’s results include, but are not limited to, regulatory approvals, product demand, market acceptance, impact of competitive products and prices, product development, commercialization or technological difficulties, the success or failure of negotiations and trade, legal, social and economic risks, and the risks associated with the adequacy of existing cash resources. Additional factors that could cause or contribute to differences between the Company’s actual results and forward-looking statements include, but are not limited to, those risks discussed in the Company’s filings with the U.S. Securities and Exchange Commission. Readers are cautioned that actual results (including, without limitation, the timing for and results of the Company’s commercial and regulatory plans for Dario™) may differ significantly from those set forth in the forward-looking statements. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.

LabStyle Innovations Corporate and Media Contact
Yael Ayalon
Marketing Director
yaela@mydario.com
+972-54-9474380

LabStyle Innovations Investor Relations Contact
Hayden IR
Rob Fink / Brett Maas
DRIO@HaydenIR.com
+1-646-415-8972 / +1-646-536-7331

$DFBG Announces #Acquisition of #SWIMS Brand

Differential Brands Group Inc. (Nasdaq:DFBG) (“Differential Brands” or the “Company”) announced today that it has completed the acquisition of SWIMS AS (“SWIMS”), a Scandinavian lifestyle brand best known for its range of fashion-forward, water-resistant footwear and sportswear that artfully balances performance, comfort and style. SWIMS distributes its full range of footwear, swimwear, outerwear, ready-to-wear and accessories worldwide through high-end department stores, independent specialty stores, and luxury resorts. The Company also sells product through its own website and through ten licensed SWIMS-branded stores.

The transaction is expected to be immediately accretive for Differential Brands. The acquisition and related expenses were financed through a combination of Differential’s common stock totaling approximately 700,000 shares, certain warrants and cash. Differential is also pleased to acquire such a high-quality brand at an attractive contribution multiple below 6.5 times. The Company obtained a $13.0 million bridge financing facility in order to facilitate the closing of the transaction.

Michael Buckley, Chief Executive Officer of Differential Brands, commented, “This marks the first acquisition for Differential Brands, and we are thrilled to be adding SWIMS, a sought-after lifestyle brand, to our portfolio. SWIMS’ unique, global footprint in the water-resistant footwear and apparel category aligns well with our strategy to build a portfolio of complementary, premium brands that consumers are passionate about. We believe that SWIMS offers significant growth opportunity through increased brand awareness and continued expansion in both the U.S. and international markets. The transaction also adds a strong sales network around the world to build our existing Robert Graham and Hudson businesses.”

Alex Eskeland, President and Co-Founder of SWIMS, commented, “We are excited to partner with the Differential Brands team to capitalize on their expertise and infrastructure, as well as leverage their omni-channel distribution strategy to expand SWIMS’ presence, including in the U.S. We’re also looking forward to helping diversify the geographic presence of Robert Graham and Hudson through our well-developed international network.”

About Differential Brands Group

Differential Brands Group Inc. (Nasdaq: DFBG) is a platform that focuses on branded operating companies in the premium apparel, footwear and accessories sectors. Our focus is on organically growing our brands through a global, omni-channel distribution strategy while continuing to seek opportunities to acquire accretive, complementary, premium brands.

Our current brands are Hudson®, a designer and marketer of women’s and men’s premium, branded denim and apparel, Robert Graham®, a sophisticated, eclectic apparel and accessories brand seeking to inspire a global movement, and SWIMS AS, a Scandinavian lifestyle brand best known for its range of fashion-forward, water-resistant footwear, apparel and accessories. For more information, please visit Differential’s website at: www.differentialbrandsgroup.com.

About SWIMS AS

SWIMS was initially established to transform the traditional, utilitarian galosh into a tasteful lifestyle item with bold personality. While Scandinavia is famous for clean and minimalistic design, Norwegian brands are particularly functional and have to adapt to the highly contrasting seasons they face at home. Norwegians, famous for fearlessly and happily adapting between the heaviest winter months to the ‘warm’ summer months on the fjord, therefore require ultimate versatility and functionality. SWIMS enables the typical urban Scandinavian to look sleek with a touch of cheekiness, comfort and ultimate functionality fit for both slushy winter days in the city and warm days out on the boat during the summer season.

This release contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended. The matters discussed in this news release involve estimates, projections, goals, forecasts, assumptions, risks and uncertainties that could cause actual results or outcomes to differ materially from those expressed in the forward-looking statements. All statements in this news release that are not purely historical facts are forward-looking statements, including statements containing the words “may,” “will,” “expect,” “anticipate,” “intend,” “estimate,” “continue,” “believe,” “plan,” “project,” “will be,” “will continue,” “will likely result” or similar expressions. Any forward-looking statement inherently involves risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to: the anticipated benefits of the merger on its financial results, business performance and product offerings, the Company’s ability to successfully integrate the SWIMS business and realize cost savings and any other synergies, the risk that the credit ratings of the company or its subsidiaries may be different from what the Company expects, continued acceptance of our product, product demand, competition, capital adequacy, general economic conditions and the potential inability to raise additional capital if required; the risk that the Company will be unsuccessful in gauging fashion trends and changing customer preferences; the risk that changes in general economic conditions, consumer confidence, or consumer spending patterns will have a negative impact on the Company’s financial performance; the highly competitive nature of the Company’s business in the United States and internationally and its dependence on consumer spending patterns, which are influenced by numerous other factors; the Company’s ability to respond to the business environment and fashion trends; continued acceptance of the Company’s brands in the marketplace; and other risks. The Company discusses certain of these factors more fully in its additional filings with the SEC, including its last annual report on Form 10-K and quarterly report on Form 10-Q filed with the SEC, and this release should be read in conjunction with those reports, together with all of the Company’s other filings, including current reports on Form 8-K, through the date of this release. The Company urges you to consider all of these risks, uncertainties and other factors carefully in evaluating the forward-looking statements contained in this release.

Any forward-looking statement is based on information current as of the date of this document and speaks only as of the date on which such statement is made, and the Company undertakes no obligation to update these statements to reflect events or circumstances after the date on which such statement is made. Readers are cautioned not to place undue reliance on forward-looking statements.

Investor Relations:
Differential Brands Group Inc.
Hamish Sandhu, 323.558.5188
or
Media Inquiries:
Robert Graham
Sophia Manata, 646.625.5123
smanata@robertgraham.us

$CERU Receives #FDA #FastTrack Designation for #CRLX101 in #Ovarian #Cancer

Cerulean Pharma Inc. (NASDAQ:CERU), a clinical-stage company developing nanoparticle-drug conjugates (NDCs), today announced that the U.S. Food and Drug Administration (FDA) granted Fast Track designation for Cerulean’s lead nanoparticle-drug conjugate, CRLX101, in combination with paclitaxel, for the treatment of platinum-resistant ovarian carcinoma, fallopian tube or primary peritoneal cancer.

“We appreciate the FDA’s acknowledgement of CRLX101’s potential in an area of significant unmet medical need,” said Christopher D. T. Guiffre, President and Chief Executive Officer of Cerulean. “We are encouraged by the profound treatment effect observed early in the ongoing clinical trial with the GOG Foundation, Inc. (GOG), and we look forward to working closely with the FDA as we endeavor to bring a new treatment option to women living with platinum-resistant ovarian cancer.”

CRLX101 is being evaluated in combination with weekly paclitaxel for the treatment of recurrent platinum-resistant ovarian carcinoma in a Phase 1b/2 clinical trial. Data from the Phase 1b portion of the trial were the subject of an oral presentation at the Gynecologic Oncology 2016 Conference in May. These data showed that five of the first nine patients (56%) enrolled in the trial achieved partial responses. Of note, five of the nine patients enrolled in the Phase 1b trial previously failed Avastin^® (bevacizumab) and three of these five patients achieved partial responses. Cerulean is conducting this trial in collaboration with the GOG and expects to provide an update at the European Society for Medical Oncology 2016 Congress.

In 2015, CRLX101 was granted Orphan Drug designation for the treatment of ovarian cancer.

The FDA’s Fast Track Program is designed to facilitate the development and expedite the review of new drugs that are intended to treat serious conditions and that demonstrate the potential to address unmet medical needs. Drugs that receive this designation benefit from more frequent communications and meetings with FDA to review the drug’s development plan, including the design of the proposed clinical trials and the extent of data needed for approval.

About CRLX101

CRLX101 is a nanoparticle-drug conjugate (NDC) designed to concentrate in tumors and slowly release its anti-cancer payload, camptothecin, inside tumor cells. CRLX101 inhibits topoisomerase 1 (topo 1), which is involved in cellular replication, and also inhibits hypoxia-inducible factor-1α (HIF-1α), which research suggests is a master regulator of cancer cell survival mechanisms. CRLX101 has shown activity in four different tumor types, both as monotherapy and in combination with other cancer treatments. CRLX101 is in Phase 2 clinical development and has been dosed in more than 350 patients. The U.S. FDA has granted CRLX101 Orphan Drug designation for the treatment of ovarian cancer, Fast Track designation in combination with paclitaxel for platinum-resistant ovarian carcinoma, fallopian tube or primary peritoneal cancer, and Fast Track designation in combination with Avastin^® in metastatic renal cell carcinoma.

About GOG Foundation, Inc. (GOG Foundation)

The GOG Foundation, Inc. (GOG Foundation) is an independent international non-profit organization with the purpose of promoting excellence in the quality and integrity of clinical and basic scientific research in the field of gynecologic malignancies. The GOG Foundation is committed to maintaining the highest standards in clinical trials development, execution, analysis and distribution of results. Continuous evaluation of the GOG Foundation’s processes is utilized in order to constantly improve the quality of patient care. The GOG Foundation conducts clinical trials for patients with a variety of gynecologic malignancies, including cancers that arise from the ovaries, uterus, cervix, vagina, and vulva. The GOG Foundation is a separate entity from the National Clinical Trials Network groups that are funded by the National Cancer Institute.

About Cerulean Pharma

The Cerulean team is committed to improving treatment for people living with cancer. We apply our Dynamic Tumor Targeting™ Platform to create a portfolio of NDCs designed to selectively attack tumor cells, reduce toxicity by sparing the body’s normal cells, and enable therapeutic combinations. Our first platform-generated NDC clinical candidate, CRLX101, is in multiple clinical trials in combination with other cancer treatments, all of which aim to unlock the power of combination therapy. Our second platform-generated NDC clinical candidate, CRLX301, is in Phase 2a clinical development. For more information, please visit www.ceruleanrx.com.

Cautionary Note on Forward Looking Statements

Any statements in this press release about our future expectations, plans and prospects, including statements about the clinical development of our product candidates, statements about the sufficiency of cash and cash equivalents to fund our operations, debt service and other scheduled expenditures and other statements containing the words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “hypothesize,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “would,” and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the uncertainties inherent in the initiation and completion of clinical trials, availability and timing of data from ongoing and future clinical trials and the results of such trials, whether preliminary results from a clinical trial will be predictive of the final results of that trial or whether results of early clinical trials will be indicative of the results of later clinical trials, expectations for regulatory approvals, availability of funding sufficient for our foreseeable and unforeseeable operating expenses and capital expenditure requirements and other factors discussed in the “Risk Factors” section of our Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on May 2, 2016, and in other filings that we make with the Securities and Exchange Commission. In addition, any forward-looking statements included in this press release represent our views only as of the date of this release and should not be relied upon as representing our views as of any subsequent date. We specifically disclaim any obligation to update any forward-looking statements included in this press release.

Avastin is a registered trademark of Genentech, Inc.

Cerulean Pharma
Nicole P. Jones, 781-209-6385
Director, Investor Relations and Corporate Communications
njones@ceruleanrx.com

$GLDC & #UtzQualityFoods Announce Definitive #Merger Agreement

BIRMINGHAM, Ala. and HANOVER, Pa., July 19, 2016  — Golden Enterprises, Inc. (the “Company”) (NASDAQ: GLDC) and Utz Quality Foods, Inc. of Hanover, PA (“Utz”) announced that they entered into a definitive merger agreement on July 18, 2016, pursuant to which Utz will acquire the Company and Company stockholders will receive $12.00 per share in cash. This price represents a premium of approximately 71 percent over the Company’s 30-day average closing trading price of $7.00.

“After conducting a review of strategic alternatives by a Special Committee consisting of independent members of the Company’s Board of Directors, we believe that this is an excellent transaction for our stockholders, our customers and our employees,” said Mark McCutcheon, Chief Executive Officer of the Company.   “This merger will allow the Golden Flake brand to continue to grow in our core southeastern markets, while expanding the product selections for our consumers.  Utz is a very community oriented company and we look forward to the future that Utz and Golden Flake will create together.”

Utz Quality Foods, Inc. is a privately held snack food company, founded in 1921 by William and Salie Utz.  They began making potato chips out of their home in Hanover, in much the same way Frank Mosher, Mose Lischkoff and Helen Freidman began Golden Flake in 1923.   The Bashinsky family began their snack food legacy when they purchased the business in 1946.  During their tenure the Company grew from a small local operation to the multi-state corporation it is today.

“We are excited about the opportunity to partner with Golden Flake,” said Dylan Lissette, Chief Executive Officer of Utz. “The two companies are very similar both in mission and values, and each has a team of dedicated associates. Golden Flake’s product line, market coverage, and manufacturing facilities blend well with Utz’s desire to expand and grow our markets in the south.”  Both management teams recognize the value of the “plus one strength” gained from the synergies of each company.  The Golden Flake product lines and production capabilities will complement the Utz product portfolio, which includes Utz, Zapps, “Dirty”, Bachman, Wachusett, Snikiddy and Good Health.

“Our company has viewed Golden Flake as a leader in the industry.  Their culture, quality line of products, and dedicated people, through the vision and leadership that Mr. Bashinsky established, is a wonderful fit within our company,” said Mr. Lissette. Golden Flake will operate as a separate subsidiary under the leadership of its current management team and continue to be an important part of Birmingham as “The South’s Original Potato Chip!”

Subject to antitrust approval and satisfaction of other customary closing conditions, the transaction is expected to close in the fourth quarter of 2016. Following the execution of the merger agreement, stockholders representing a majority of the voting shares of Golden Enterprises delivered a written consent approving and adopting the merger agreement.  The merger agreement includes a three-day period during which the Company’s Board can consider an unsolicited alternative proposal that it concludes in good faith (after consultation with outside legal counsel and the financial advisor) is more favorable from a financial point of view to the stockholders of the Company than the transaction contemplated by the merger agreement.

North Point Advisors, LLC acted as financial advisor to the Special Committee of the Board of Directors of Golden Enterprises.  Sirote & Permutt, PC acted as legal counsel to the Special Committee of the Board of Directors of Golden Enterprises.  Sandler O’Neill acted as financial advisor to Utz.  Cozen O’Connor acted as legal counsel to Utz.

NOTE: This press release contains forward-looking statements. Readers are cautioned that such forward-looking statements involve risks and uncertainties that could cause actual events or our actual results to differ materially from those expressed in any such forward-looking statements. Such forward-looking statements include the possible benefits of the proposed Golden Enterprises acquisition to the Utz business. Readers are directed to Golden Enterprises’ periodic and other reports filed with the Securities and Exchange Commission (SEC) for a description of such risks and uncertainties. Neither Golden Enterprises nor Utz undertakes any obligation to update any forward-looking statements.

$EXPI #AgentOwned #Cloud #Brokerage Engine Driven by #AR #VR, Like #PokemonGo

$CPLP #CharterRate Reduction, #Hyundai Merchant Marine Financial Restructuring

$COYN #COPsync #Presentation Now Available for #OnDemand Viewing

Company invites individual and institutional investors as well as advisors to log-on to VirtualInvestorConferences.com to view its presentation

DALLAS, July 18, 2016  – COPsync, Inc. (NASDAQ: COYN) announced today that the July 14 presentation from chief executive officer Mr. Ronald A. Woessner is now available for on-demand viewing at VirtualInvestorConferences.com. The COPsync Network™ is the nation’s only system connecting law enforcement officers and agencies nationwide, and provides access to a national database of non-adjudicated law enforcement information and real-time communication capability to connected agencies, even those thousands of miles apart, and the COPsync911™ threat-alert service for schools, government buildings, hospitals and other potentially at-risk facilities.

COPsync’s presentation will be available 24/7 for 90 days. Investors and advisors may download presentation materials from the “virtual trade booth” for the next three weeks.

Learn more about the event at www.VirtualInvestorConferences.com.

COPsync has created the nation’s only SaaS-based software platform that connects law enforcement agencies to provide critical real-time, information sharing, communication and data interoperability through the COPsync Network and the Company’s companion service COPsync911. Thousands of officers in twelve states are using the COPsync Network to prevent officer deaths and injuries and interdict all manner of violent and illegal activity. The Company has gained a significant footprint in Texas and has begun expansion in other states. The COPsync911 companion service connects potentially at-risk facilities directly to the closest patrol officers, regardless of agency jurisdiction, and provides the first responders up-to-the-second situational information through its live communication feature. Both the COPsync Network and COPsync911 are provided via a SaaS business model, which has the potential to create a recurring high-margin revenue stream.

About COPsync, Inc.

COPsync, Inc. (NASDAQ: COYN) is a technology company that improves law enforcement communication in a manner that saves officers’ lives and helps them prevent and respond more quickly to crime. Officers have instant access to actionable, mission-critical non-adjudicated law enforcement information created by other law enforcement agencies and are now able to communicate in real-time with other officers and agencies, even those hundreds and thousands of miles away. The COPsync Network™ also eliminates manual processes and increases officer productivity by enabling officers to write electronic tickets, accident reports, DUI forms, arrest forms and incident and offense reports. COPsync’s threat-alert system, COPsync911™, enables schools, courts, hospitals, and other potentially at-risk facilities to automatically and silently send emergency alerts directly to local law enforcement officers in their patrol cars during a crisis, thereby speeding first responder response times and saving minutes when seconds count. The company also sells VidTac®, a law enforcement software-driven in-vehicle video system. Visit www.copsync.com and www.copsync911.com for more information.

About VirtualInvestorConferences.com

Since 2010, VirtualInvestorConferences.com, created by BetterInvesting (NAIC) and PRNewswire, has been the only monthly virtual investor conference series that provides an interactive forum for presenting companies to meet directly with investors using a graphically-enhanced online platform.

Designed to replicate the look and feel of location-based investor conferences, Virtual Investor Conferences unites PR Newswire’s leading-edge online conferencing and investor communications capabilities with BetterInvesting’s extensive retail investor audience network.

Safe Harbor Statement

Statements in this release that are not purely historical facts or that depend upon future events, including statements about forecasts of earnings, revenue, product development, sales or other statements about anticipations, beliefs, expectations, intentions, plans or strategies for the future, may be forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. For example, statements containing words like “expect”; “believe”; “confident”; “estimated”; “future”; “plan”; “planning”; “projected”; “potential”; “strategy”; “pursuing”; “objective” or such other variations thereon or comparable terminology, express management’s current views concerning future events, trends, contingencies or results, which may be considered forward-looking statements. Readers are cautioned not to place undue reliance on forward-looking statements. All forward-looking statements are based on information available to the Company on the date this release was issued. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Any forward-looking statements involve risks and uncertainties that could cause actual events or results to differ materially from the events or results described in the forward-looking statements. The Company may not succeed in adequately addressing and managing these and other risks. Further information regarding factors that could affect the Company’s financial, operating and other results can be found in the risk factors section of the Company’s Annual Report on Form 10-K for the year ended December 31, 2015, filed with the Securities and Exchange Commission.

$GSS Appointment of #GilClausen to #BoardofDirectors

TORONTO, July 18, 2016  – Golden Star Resources Ltd. (“Golden Star” or the “Company”) is pleased to announce that Gil Clausen is joining the Company’s Board of Directors, with immediate effect.

Mr. Clausen is the President of a division of Yamana Gold Inc., and former President, Chief Executive Officer and Director of Augusta Resource Corporation.  He also serves as an independent director of Plata Latina Minerals Corporation. With over 30 years of executive, financial, developmental and operational industry experience, Mr. Clausen has been responsible for executing growth strategies for mining companies on a range of continents and across a variety of commodities.  He is a Professional Engineer and holds a Bachelor’s degree and a Master’s degree, each in Mining Engineering from Queens University, Canada. He is also a graduate of a Queen’s University executive business program.

Tim Baker, Chairman of Golden Star, commented:

“I am pleased to welcome Gil Clausen to Golden Star’s Board of Directors.  He brings solid operational and technical experience through his background in mining engineering, in addition to his wealth of corporate experience gained in senior roles with a number of large mining companies.  He has a proven track record of delivering strong financial gains for shareholders and offers comprehensive knowledge of board governance, operations, corporate and project finance, strategic planning and investor relations.  I look forward to working closely with Gil as Golden Star continues on its path to become a high grade, low cost gold producer.”

Company Profile

Golden Star is an established gold mining company that owns and operates the Wassa and Prestea mines situated on the prolific Ashanti Gold Belt in western Ghana, Africa. Listed on the NYSE MKT, the TSX, and the GSE, Golden Star is strategically focused on increasing operating margins and cash flow through the development of two high grade, low cost underground mines both in conjunction with existing open pit operations. The Wassa Underground commenced pre-commercial production in mid-2016 and the Prestea Underground is expected to commence production in mid-2017. Both projects are fully funded and on track to begin production as expected. Production in 2016 is expected to be between 180,000–205,000 ounces of gold with costs of US$815-US$925 per ounce.

$HDSN Awarded ~$400 Million #DOD Contract

Hudson Technologies, Inc. (NASDAQ:HDSN) announced that it has been awarded, as prime contractor, a five-year contract including a five-year renewal option, by the United States Defense Logistics Agency (“DLA”) with an estimated maximum value over the term of the agreement of $400 million in sales to the Department of Defense. The fixed price contract is for the management and supply of refrigerants, compressed gases, cylinders and related items to US Military Commands and Installations, Federal civilian agencies and Foreign Militaries. Primary users include the US Army, Navy, Air Force, Marine Corps and Coast Guard.

Kevin Zugibe, Chairman and CEO of Hudson Technologies, commented, “This award was two years in the making and represents a transformative win for Hudson. In January of 2015, we executed a strategic acquisition of a West Coast based supplier of refrigerants and compressed gases to expand our presence in the industrial gas sectors. This acquisition provided us with complementary capabilities to subsequently bid on, and ultimately win, this large DoD contract. While the ultimate amount of revenue will depend on order levels, this award solidifies our presence in the refrigerants and industrial gas sectors and we believe will contribute considerable future revenue and earnings growth.”

About Hudson Technologies

Hudson Technologies, Inc. is a leading provider of innovative solutions to recurring problems within the refrigeration industry. Hudson’s proprietary RefrigerantSide^® Services increase operating efficiency and energy savings, and remove moisture, oils and other contaminants frequently found in the refrigeration circuits of large comfort cooling and process refrigeration systems. Performed at a customer’s site as an integral part of an effective scheduled maintenance program or in response to emergencies, RefrigerantSide^® Services offer significant savings to customers due to their ability to be completed rapidly and at higher purity levels, and can be utilized while the customer’s system continues to operate. In addition, the Company sells refrigerants and provides traditional reclamation services to the commercial and industrial air conditioning and refrigeration markets. For further information on Hudson, please visit the Company’s web site at www.hudsontech.com.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995

Statements contained herein which are not historical facts constitute forward-looking statements. Such forward-looking statements involve a number of known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, but are not limited to, order levels pursuant to the Company’s agreement with DLA, changes in the laws and regulations affecting the industry, changes in the demand and price for refrigerants (including unfavorable market conditions adversely affecting the demand for, and the price of, refrigerants), the Company’s ability to source refrigerants, regulatory and economic factors, seasonality, competition, litigation, the nature of supplier or customer arrangements that become available to the Company in the future, adverse weather conditions, possible technological obsolescence of existing products and services, possible reduction in the carrying value of long-lived assets, estimates of the useful life of its assets, potential environmental liability, customer concentration, the ability to obtain financing, any delays or interruptions in bringing products and services to market, the timely availability of any requisite permits and authorizations from governmental entities and third parties as well as factors relating to doing business outside the United States, including changes in the laws, regulations, policies, and political, financial and economic conditions, including inflation, interest and currency exchange rates, of countries in which the Company may seek to conduct business, the Company’s ability to successfully integrate any assets it acquires from third parties into its operations, and other risks detailed in the Company’s 10-K for the year ended December 31, 2015 and other subsequent filings with the Securities and Exchange Commission. The words “believe”, “expect”, “anticipate”, “may”, “plan”, “should” and similar expressions identify forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date the statement was made.

Investor Relations:
Institutional Marketing Services (IMS)
John Nesbett/Jennifer Belodeau
203-972-9200
jnesbett@institutionalms.com
or
Company:
Hudson Technologies, Inc.
Brian F. Coleman, 845-735-6000
President & COO
bcoleman@hudsontech.com

$PRKR Enters #Patent #License & #SettlementAgreement w/ $SSNLF

JACKSONVILLE, Fla., July 18, 2016  — ParkerVision, Inc. (NASDAQ:PRKR), a leading developer and marketer of radio frequency technologies used in advanced wireless solutions, announced today that it has entered into a settlement and patent license agreement with Samsung Electronics Co., Ltd. and its affiliates (collectively, “Samsung”) for the perpetual, worldwide license of ParkerVision’s current patent portfolio, subject to certain exclusions. In conjunction with this agreement, ParkerVision will file a motion to terminate Samsung from a pending U.S. International Trade Commission investigation and dismiss its claims against Samsung in two United States District Court cases. The companies agreed not to disclose the specific financial terms of the agreement.

ParkerVision’s Chairman and CEO, Jeffrey Parker, commented, “Samsung is a world leader in technology and innovation, and we are pleased to welcome Samsung as a licensee of our technologies and to dismiss the outstanding litigation between the parties.”

About ParkerVision

ParkerVision, Inc. designs, develops and markets its proprietary radio-frequency (RF) technologies, which enable advanced wireless solutions for current and next generation communications networks. Protected by a highly-regarded, worldwide patent portfolio, the Company’s solutions for wireless transfer of RF waveforms address the needs of a broad range of wirelessly connected devices for high levels of RF performance coupled with best-in-class power consumption.  For more information please visit www.parkervision.com.  (PRKR-G).

Safe Harbor Statement

This press release contains forward-looking information.  Readers are cautioned not to place undue reliance on any such forward-looking statements, each of which speaks only as of the date made.  Such statements are subject to certain risks and uncertainties which are disclosed in the Company’s SEC reports, including the Form 10-K for the year ended December 31, 2015 and the Forms 10-Q for the quarters ended March 31, 2016.  These risks and uncertainties could cause actual results to differ materially from those currently anticipated or projected.

Contact:
Cindy Poehlman  
Chief Financial Officer  
ParkerVision, Inc.
904-732-6100
cpoehlman@parkervision.com

or

Don Markley 
The Piacente Group
212-481-2050
parkervision@tpg-ir.com

$CREE to #Sell #Wolfspeed to $IFNNY for $850 Million #Cash

Cree, Inc. (Nasdaq: CREE), a market leader in LED lighting, today announced execution of a definitive agreement to sell its Wolfspeed Power and RF division (“Wolfspeed”), which includes the silicon carbide substrate business for power, RF and gemstone applications, to Infineon Technologies AG (FSE: IFX / OTCQX: IFNNY) for $850 million in cash.

In 2015, the Company announced its strategy to become a more focused LED lighting company. As part of that strategy, the Company also announced the proposed IPO of Wolfspeed to create a more focused Power and RF management team, raise capital to fuel Wolfspeed’s growth and unlock value for Cree shareholders.

Subsequent to that announcement, the Company was approached by several parties interested in acquiring the business directly. After evaluating the strategic options, the Company concluded that selling Wolfspeed to Infineon is the best decision for our shareholders, employees and customers.

“Selling Wolfspeed to Infineon speeds our transition to a more focused LED lighting company while providing significant resources to accelerate our growth,” stated Chuck Swoboda, Cree chairman and CEO. “Divesting Wolfspeed is targeted to reduce short-term profits, but increase free cash flow. We believe this is the right decision for the company, as it unlocks value, increases management focus on the core business and supports our mission to build a more valuable LED lighting technology company. We target using the capital raised, combined with improved free cash flow, to fund select M&A, as well as to support additional stock buybacks.”

The business to be acquired by Infineon generated pro-forma revenue of $173 million in the last twelve months ending March 27, 2016*. Both Cree’s Board of Directors and Infineon’s Supervisory Board have approved the transaction. J.P. Morgan Securities LLC served as the company’s financial adviser on the transaction. The closing of the transaction is expected by the end of calendar year 2016, and is subject to customary closing conditions and regulatory approvals, including HSR and CFIUS clearance. The Company targets approximately $585 million of net proceeds after tax and other deal related costs.

*Attached as an exhibit to this press release is a reconciliation schedule comparing Cree’s historical segment information presentation to the pro-forma segment information for revenue, gross profit and gross margin for the segments reclassified to reflect the assets to be sold as part of the Wolfspeed business. These assets include certain assets formerly part of the LED Product segment relating to the silicon carbide substrate business for power, RF and gemstone applications described above.

FY16 Q4 Business Update

Commercial lighting gained momentum in Q4, as orders increased, customer service improved significantly and nine new products or significant upgrades were released. LED Products also executed well, delivering solid quarter over quarter revenue growth.

Preliminary revenue results for Q4 were at the upper end of the Company’s target range at approximately $388 million.

• Lighting Products revenue was in line with the expectations for this segment in the Company’s previously announced revenue targets at approximately $197 million.
• LED Products revenue was higher than the expectations for this segment in the Company’s previously announced revenue targets at approximately $160 million due in part to the benefit of licensing revenue.
• Wolfspeed revenue was in line with the expectations for this segment in the Company’s previously announced revenue targets at approximately $31 million.

The Company will provide a complete review of Q4 results and FY17 Q1 outlook on its regularly scheduled financial results call on August 16^th at 5:00 p.m. EDT.

Conference Call:

The Company plans to hold a conference call today at 8:00 a.m. EDT to discuss the transaction and these preliminary results. The conference call will be available to the public through a live audio web broadcast via the internet. For webcast details, visit Cree’s website at investor.cree.com/events.cfm.

About Cree, Inc.

Cree is leading the LED lighting revolution and making energy-wasting traditional lighting technologies obsolete through the use of energy-efficient, mercury-free LED lighting. Cree is a market-leading innovator of lighting-class LEDs, lighting products and semiconductor products for power and radio frequency (RF) applications.

Cree’s product families include LED lighting systems and bulbs, blue and green LED chips, high-brightness LEDs, lighting-class power LEDs, power-switching devices and RF devices. Cree’s products are driving improvements in applications such as general illumination, electronic signs and signals, power supplies and inverters.

For additional product and Company information, please refer to www.cree.com.

Forward Looking Statements:

The schedules attached to this release are an integral part of the release. This press release contains forward-looking statements involving risks and uncertainties, both known and unknown, that may cause actual results to differ materially from those indicated in the forward-looking statements. Forward-looking statements by their nature address matters that are, to different degrees, uncertain, such as statements about the potential timing or consummation of the proposed transaction or the anticipated benefits thereof, including future financial and operating results. Actual results, including with respect to our targets and prospects, could differ materially due to a number of factors, including the risk that the transaction may be delayed or may not occur; the ability to obtain regulatory approval or the possibility that such regulatory approval may result in the imposition of conditions that could cause the parties to abandon the transaction; the risk that one or more of the conditions to closing of the transaction may not be satisfied; the possibility that anticipated benefits of the proposed transaction will not be realized, including the amount of cash to be realized by Cree from the transaction or its resulting ability to pursue select strategic transactions and stock repurchases; potential business uncertainty, including changes to existing business relationships during the pendency before closing that could affect Cree’s financial performance; that we may not obtain sufficient orders to achieve our targeted revenues; price competition in key markets; the risk that we or our channel partners are not able to develop and expand customer bases and accurately anticipate demand from end customers, which can result in increased inventory and reduced orders as we experience wide fluctuations in supply and demand; the risk that our commercial lighting results will continue to suffer if new issues arise regarding the new ERP system we implemented in the third quarter of fiscal 2016; the risk that we may experience production difficulties that preclude us from shipping sufficient quantities to meet customer orders or that result in higher production costs and lower margins; our ability to lower costs; the risk that our results will suffer if we are unable to balance fluctuations in customer demand and capacity; product mix; risks associated with the ramp-up of production of our new products, and our entry into new business channels different from those in which we have historically operated; the risk that customers do not maintain their favorable perception of our brand and products, resulting in lower demand for our products; the risk that our products fail to perform or fail to meet customer requirements or expectations, resulting in significant additional costs, including costs associated with the potential recall of our products; the risk that retail customers may alter promotional pricing, increase promotion of a competitor’s products over our products or reduce their inventory levels, all of which could negatively affect product demand; the risk that our equity method investments may experience periods of significant stock price volatility causing us to recognize fair value losses on our investment; the risk that we have an increasingly complex supply chain and its ability to scale to enable maintaining a sufficient supply of raw materials; ongoing uncertainty in global economic conditions, infrastructure development or customer demand that could negatively affect product demand, collectability of receivables and other related matters as consumers and businesses may defer purchases or payments, or default on payments; the risk we may be required to record a significant charge to earnings if our goodwill or amortizable assets become impaired; our ability to complete development and commercialization of products under development, such as our pipeline of improved LED chips, LED components and LED lighting products; risks resulting from the concentration of our business among few customers, including the risk that customers may reduce or cancel orders or fail to honor purchase commitments; risks related to our multi-year warranty periods for LED lighting products; risks associated with acquisitions, divestitures or investments; the rapid development of new technology and competing products that may impair demand or render our products obsolete; the potential lack of customer acceptance for our products; risks associated with ongoing litigation; and other factors discussed in our filings with the Securities and Exchange Commission (SEC), including our report on Form 10-K for the fiscal year ended June 28, 2015, and subsequent reports filed with the SEC. These forward-looking statements represent Cree’s judgment as of the date of this release. Except as required under the U.S. federal securities laws and the rules and regulations of the SEC, Cree disclaims any intent or obligation to update any forward-looking statements after the date of this release, whether as a result of new information, future events, developments, changes in assumptions or otherwise.

Cree, Inc.
Raiford Garrabrant, 919-407-7895
Director, Investor Relations
Fax: 919-407-5615
investorrelations@cree.com

$SUNW Chosen to Oversee #Solar Energy Projects for $AMZN #Amazon Fulfillment Centers

$CCCL Regains #Compliance with #NASDAQ #ListingRequirements

JINJIANG, China, July 14, 2016  — China Ceramics Co., Ltd. (NASDAQ Capital Market: CCCL) (“China Ceramics” or the “Company”), a leading Chinese manufacturer of ceramic tiles used for exterior siding and for interior flooring and design in residential and commercial buildings, today announced receipt of a letter from the NASDAQ Stock Market (“Nasdaq”) stating that the Company has regained compliance with Nasdaq’s Listing Rule 5550(a)(2) minimum closing bid price requirement and that the matter is now closed.

China Ceramics had previously been notified by Nasdaq that it was not in compliance with the minimum bid price rule because its common stock failed to meet the closing bid price of $1.00 or more for 30 consecutive business days. In order to regain compliance with the rule, the Company was required to maintain a minimum closing bid price of $1.00 or more for at least 10 consecutive trading days. This requirement was met on June 12, 2016, the tenth consecutive trading day when the closing bid price of the Company’s common stock was over $1.00.  The Company undertook a reverse stock split on June 28, 2016, to cure the Nasdaq listing deficiency.

“Regaining compliance with Nasdaq’s continued listing requirements in our securities on the Nasdaq Capital Market is important for the Company and our shareholders,” commented Jiadong Huang, Chief Executive Officer of China Ceramics.  “With this issue behind us, management will continue to pursue its objectives of strengthening the Company’s core business and maximizing shareholder value.”

About China Ceramics Co., Ltd.

China Ceramics Co., Ltd. is a leading manufacturer of ceramic tiles in China. The Company’s ceramic tiles are used for exterior siding, interior flooring, and design in residential and commercial buildings. China Ceramics’ products, sold under the “Hengda” or “HD”, “Hengdeli” or “HDL”, the “TOERTO” and “WULIQIAO” brands, and the “Pottery Capital of Tang Dynasty” brands, are available in over 2,000 style, color and size combinations and are distributed through a network of exclusive distributors as well as directly to large property developers. For more information, please visit http://www.cceramics.com .

Safe Harbor Statement

Certain of the statements made in this press release are “forward-looking statements” within the meaning and protections of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements include statements with respect to our beliefs, plans, objectives, goals, expectations, anticipations, assumptions, estimates, intentions, and future performance, and involve known and unknown risks, uncertainties and other factors, which may be beyond our control, and which may cause the actual results, performance, capital, ownership or achievements of the Company to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements. Forward-looking statements in this press release include, without limitation, the continued stable macroeconomic environment in the PRC, the PRC real estate and construction sectors continuing to exhibit sound long-term fundamentals, our ability to bring additional capacity online going forward as our business improves, our customers continuing to adjust to our product price increases, our ability to sustain our average selling price increases and to continue to build volume in the quarters ahead, and whether our enhanced marketing efforts will help to produce wider customer acceptance of the new price points. All statements other than statements of historical fact are statements that could be forward-looking statements. You can identify these forward-looking statements through our use of words such as “may,” “will,” “anticipate,” “assume,” “should,” “indicate,” “would,” “believe,” “contemplate,” “expect,” “estimate,” “continue,” “plan,” “point to,” “project,” “could,” “intend,” “target” and other similar words and expressions of the future.

All written or oral forward-looking statements attributable to us are expressly qualified in their entirety by this cautionary notice, including, without limitation, those risks and uncertainties described in our annual report on Form 20-F for the year ended December 31, 2015 and otherwise in our SEC reports and filings. Such reports are available upon request from the Company, or from the Securities and Exchange Commission, including through the SEC’s Internet website at http://www.sec.gov . We have no obligation and do not undertake to update, revise or correct any of the forward-looking statements after the date hereof, or after the respective dates on which any such statements otherwise are made.

$BCLI to Announce #TopLine #Results #US #Phase2 #Study of #NurOwn in #ALS

Conference Call and Live Webcast at 10am Eastern Time

HACKENSACK, N.J. and PETACH TIKVAH, Israel, July 14, 2016 /PRNewswire/ — BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, will announce results from the recently completed Phase 2 Study of NurOwn® in Patients with ALS on Monday, July 18, 2016.  The Company will host a conference call and webcast with slides at 10:00am Eastern Time.

About BrainStorm Cell Therapeutics Inc.
BrainStorm Cell Therapeutics Inc. is a biotechnology company engaged in the development of first-of-its-kind adult stem cell therapies derived from autologous bone marrow cells for the treatment of neurodegenerative diseases. The Company holds the rights to develop and commercialize its NurOwn®technology through an exclusive, worldwide licensing agreement with Ramot, the technology transfer company of Tel Aviv University.  NurOwn®has been administered to over 30 patients with ALS in clinical trials conducted in Israel, and is currently being studied in a randomized, double-blind, placebo-controlled clinical trial in the United States.  For more information, visit the company’s website at www.brainstorm-cell.com.

CONTACTS

Media:
Uri Yablonka, COO
Chief Operating Officer
Brainstorm Cell Therapeutics Inc.
Phone: (646) 666-3188
uri@brainstorm-cell.com

Investors:
Michael Rice
LifeSci Advisors, LLC
Phone: 646-597-6979
mrice@lifesciadvisors.com

$OPTT Announces Deployment of First Commercially Designed #PB3 #PowerBuoy

PENNINGTON, N.J., July 14, 2016  — Ocean Power Technologies, Inc. (NASDAQ:OPTT) (“OPT” or the “Company”) announced today the deployment of its commercial design of the PB3 PowerBuoy^® approximately four miles off of the coast of New Jersey.  The commercial PB3 incorporates multiple enhancements over early prototypes including a redesigned power take-off (“PTO”), a high-capacity, modular energy storage system (“ESS”) providing flexibility through expanded battery capacity, a higher voltage and efficient power management and distribution system, and a new auto-ballasting system which the Company believes allows for faster and less costly deployment.

George H. Kirby, President and Chief Executive Officer of OPT, stated, “We are delighted to announce that we now have two PB3 PowerBuoys deployed off of the coast of New Jersey, with one of them being our anticipated commercial PB3 product offering.  This deployment of our PB3 represents what we expect will be the final validation step prior to release of the product to our target customers and markets. We believe that our commercial PB3 PowerBuoy will position us to competitively address applications in our target markets such as ocean observing, oil and gas, security and defense, and communications.  As per our previously announced plan, this deployment represents a major milestone in our commercialization strategy enabling us to put our product in the hands of our customers. I am very proud of this critical company achievement.”

Dr. Mike M. Mekhiche, OPT’s Vice President of Engineering, stated, “Our recent product development efforts have focused on making what we believe are significant improvements in the reliability and survivability of our PowerBuoy, as compared to earlier iterations.  For instance, we are able to store excess power generated by the PB3 PowerBuoy in our modular ESS which we believe can provide power for some time in low ocean wave conditions, depending on payload power requirements and ESS configuration.  We have designed our commercial PB3 PowerBuoy with improvements in manufacturing, maintenance, and deployment over our prior iterations of the PowerBuoy, and we believe these may allow us to be cost-competitive as a power and communications platform for remote, offshore autonomous applications. For instance, we expect that our new auto-ballasting system could reduce the cost, improve safety, and simplify logistics of deployments.  We believe that all of these improvements will help to solidify our value proposition to potential customers.  Furthermore, we are delighted to have two PB3 PowerBuoys operating simultaneously.  The data stream from the two PowerBuoys, combined with our previously announced and on-going accelerated life testing, will allow us to share a variety of performance information with current and prospective partners and customers. To date, the accelerated life testing of our PTO systems has exceeded ten million total cumulative number of cycles. This achievement simulates the equivalent of over 1.5 years of ocean operation for the PTO fleet.”

The Company currently anticipates that this deployment will be the final validation of the PB3 prior to the anticipated March 2017 six-month lease of the PB3 PowerBuoy under a previously announced customer agreement.

About Ocean Power Technologies

Headquartered in Pennington, New Jersey, Ocean Power Technologies (NASDAQ:OPTT) is a leader in ocean wave energy conversion. OPT’s proprietary PowerBuoy^® technology is based on a scalable and modular design.  OPT specializes in cost-effective and environmentally sound ocean wave based power generation and management technology.

Forward-Looking Statements

This release may contain “forward-looking statements” that are within the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are identified by certain words or phrases such as “may”, “will”, “aim”, “will likely result”, “believe”, “expect”, “will continue”, “anticipate”, “estimate”, “intend”, “plan”, “contemplate”, “seek to”, “future”, “objective”, “goal”, “project”, “should”, “will pursue” and similar expressions or variations of such expressions. These forward-looking statements reflect the Company’s current expectations about its future plans and performance. These forward-looking statements rely on a number of assumptions and estimates which could be inaccurate and which are subject to risks and uncertainties. Actual results could vary materially from those anticipated or expressed in any forward-looking statement made by the Company. Please refer to the Company’s most recent Forms 10-Q and 10-K and subsequent filings with the SEC for a further discussion of these risks and uncertainties. The Company disclaims any obligation or intent to update the forward-looking statements in order to reflect events or circumstances after the date of this release.

Company Contact:
Mark A. Featherstone 
Chief Financial Officer of OPT
Phone: 609-730-0400

Investor Relations Contact:
Andrew Barwicki
Barwicki Investor Relations Inc.
Phone: 516-662-9461

$LOXO Receives #BreakthroughTherapy Designation from #FDA for #LOXO101

STAMFORD, Conn., July 13, 2016  — Loxo Oncology, Inc. (Nasdaq:LOXO), a biopharmaceutical company innovating the development of highly selective medicines for patients with genetically defined cancers, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to LOXO-101, a selective inhibitor of tropomyosin receptor kinase (TRK), “for the treatment of unresectable or metastatic solid tumors with NTRK-fusion proteins in adult and pediatric patients who require systemic therapy and who have either progressed following prior treatment or who have no acceptable alternative treatments.”

“We’re pleased to have been granted Breakthrough Therapy Designation for LOXO-101 and look forward to working more closely with the FDA to bring this therapy to patients with TRK fusion cancers,” said Josh Bilenker, M.D., chief executive officer at Loxo Oncology. “Data presented to date from the ongoing adult and pediatric studies of LOXO-101 have demonstrated durable anti-tumor activity across TRK fusion cancers, further validating LOXO-101’s potential to address the unmet medical need among patients with these genetically defined cancers. We remain on track to provide an enrollment update regarding the LOXO-101 Phase 2 trial in the second half of 2016.”

The FDA’s Breakthrough Therapy Designation is intended to expedite the development and review of a drug candidate that is planned for use to treat a serious or life-threatening disease or condition when preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints.

The LOXO-101 Breakthrough Therapy Designation application included data from the ongoing Phase 1 dose-escalation study of LOXO-101 in adult patients with advanced solid tumors, the ongoing Phase 1 pediatric study of LOXO-101 in patients with advanced solid tumors or primary CNS tumors, and the ongoing Phase 2 basket trial of LOXO-101 in adult cancer patients whose tumors harbor TRK fusions.

About LOXO-101
LOXO-101 is a potent, oral and selective investigational new drug in clinical development for the treatment of patients with cancers that harbor abnormalities involving the tropomyosin receptor kinases (TRKs). Growing research suggests that the NTRK genes, which encode for TRKs, can become abnormally fused to other genes, resulting in growth signals that can lead to cancer in many sites of the body. In an ongoing Phase 1 clinical trial, LOXO-101 has demonstrated encouraging preliminary efficacy. LOXO-101 is also being evaluated in a global Phase 2 multi-center basket trial in patients with solid tumors that harbor TRK gene fusions and a Phase 1 trial in pediatric patients. For additional information about the LOXO-101 clinical trials, please refer to www.clinicaltrials.gov or www.loxooncologytrials.com. Interested patients and physicians can contact the Loxo Oncology Physician and Patient Clinical Trial Hotline at 1-855-NTRK-123.

About Loxo Oncology
Loxo Oncology is a biopharmaceutical company innovating the development of highly selective medicines for patients with genetically defined cancers. Our pipeline focuses on cancers that are uniquely dependent on single gene abnormalities, such that a single drug has the potential to treat the cancer with dramatic effect. We believe that the most selective, purpose-built medicines have the highest probability of maximally inhibiting the intended target, thereby delivering best-in-class disease control and safety. Our management team seeks out experienced industry partners, world-class scientific advisors and innovative clinical-regulatory approaches to deliver new cancer therapies to patients as quickly and efficiently as possible. For more information, please visit the company’s website at www.loxooncology.com.

Forward-Looking Statements
This press release contains “forward-looking” statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: “anticipate,” “intend,” “plan,” “goal,” “seek,” “believe,” “project,” “estimate,” “expect,” “strategy,” “future,” “likely,” “may,” “should,” “will” and similar references to future periods. These statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from what we expect. Examples of forward-looking statements include, among others, the timing and success of our clinical trials, success in our collaborations and the potential therapeutic benefits of our lead product candidate or other product candidates. Further information on potential risk factors that could affect our business and its financial results are detailed in our most recent Quarterly Report on Form 10-Q, and other reports as filed from time to time with the Securities and Exchange Commission. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

Contacts for Loxo Oncology, Inc.

Company:
Jacob S. Van Naarden
Chief Business Officer
jake@loxooncology.com

Investors:
Peter Rahmer
The Trout Group, LLC
646-378-2973
prahmer@troutgroup.com

Media:
Dan Budwick
Pure Communications, Inc.
973-271-6085
dan@purecommunicationsinc.com

$ANGI Now Offering Free Membership Nationwide

Consumers Enthusiastically Embrace New Freemium Offer, Reigniting Growth in New Members, and their Visits, Searches, & Views of Service Provider Profiles

INDIANAPOLIS, July 13, 2016  — For 21 years Angie’s List (NASDAQ: ANGI) has amassed more than 10 million of the highest quality verified reviews on home services professionals in the industry, more than double its nearest competitor. Today, Angie’s List is pleased to announce that access to all those reviews is free-of-charge. In addition, two new premium membership tiers are now available, offering guarantees and value-added services beyond those reviews.

Each membership level is packed with value and builds on the other(s):

• Green: free-of-charge nationwide access to companies in more than 700 service categories; nationwide access to more than 10 million verified consumer ratings and reviews; and monthly digital form of the company’s magazine.
• Silver: includes all green features plus Angie’s Fair Price Guarantee and Angie’s Service Quality Guarantee, exclusive discounts, chat and email customer support, a bimonthly print version of the magazine for $24.99 a year.
• Gold: includes all green and silver features plus complaint resolution process and customer support via phone for $99.99 a year.

Benefits planned to be added in the coming quarters include tools for project pricing, scheduling, and financing (through partnerships), handyman chat line, a home emergency service line, instant hiring, as well as eCommerce savings.

“This is a transformative moment for the new Angie’s List as we welcome more consumers into our community so they can experience the industry-leading value and unique services that we provide,” said Angie’s List President and CEO Scott Durchslag at a launch event in New York. “Now with our new offerings, the 10-12 million visitors coming to our site each month looking for help with their home will be able to more easily find the best local service providers.”

“We completed our technology platform migration ahead of schedule, have quietly had our reviews paywall down, moved our existing members into the new tiers and have been signing up new members. This enabled us to assess organic demand and to scale the new platform more gradually, ramping up to our integrated marketing launch today.”

“I am impressed with how enthusiastically consumers are embracing our new offering, and delighted with the strong growth in new memberships and engagement we are seeing. Since dropping the reviews paywall, a number of key member metrics are re-accelerating. In the most recent week, new member sign-ups increased nearly fourfold compared to a year ago and, among those members, unique visits more than doubled. In that same period, unique members searching have more than doubled and the number of service provider profile views from those members more than doubled. Although these are early days, the data is very encouraging.  While growth in new free members will not impact near-term revenue, it is a critical milestone in executing our Profitable Growth Plan,” he added.

Angie’s List sets the industry standard for quality by allowing only those service companies that have earned high grades for demonstrating superior customer service performance; passed a criminal background check; and provided valid license attestation to advertise and offer discounts to its members.

To celebrate the new membership tiers, the first 5,000 consumers to sign up, starting today at Noon Eastern Time, at AngiesList.com will be automatically entered into a sweepstakes offering a grand prize of $20,000 for their next home improvement project. Additionally, 150 other new members will receive free upgrades to the next membership tier or one-year free at a premium tier if the initial membership was at a prize-level tier. Fifty Gold memberships and 100 Silver memberships will be awarded.

About Angie’s List
Finding a pro for a job well done is made easy online by visiting Angieslist.com. More than three million consumers nationwide use Angie’s List, a leading provider of reviews, offers and information in over 700 service categories to help them improve their homes. Built on a foundation of more than 10 million verified reviews of local service, Angie’s List connects consumers directly to its online marketplace of services, and offers unique tools and support designed to improve the local service experience for both consumers and service professionals. www.angieslist.com

CONTACTS:
Cheryl Reed, External Communications, 317-396-9134 or cherylr@angieslist.com
Leslie Arena, Investor Relations, 317-808-4527 or lesliea@angieslist.com

$INFO Updates 2016 Financial Guidance

IHS Markit Ltd. (Nasdaq: INFO), a global leader in critical information, analytics and solutions that drive economies and markets worldwide, is updating its 2016 financial guidance in connection with the previously announced completion of the merger to form IHS Markit.

This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20160713005320/en/

For the fiscal year ending November 30, 2016, including 12 months of results of IHS Inc. and approximately 4.5 months of results of Markit Ltd. from the date of closing of the merger, IHS Markit expects:

• Revenue in a range of $2.735 to $2.765 billion, including Markit contribution between $445 and $455 million;
• Adjusted EBITDA in a range of $975 to $995 million, including Markit contribution of between $190 and $200 million; and
• Adjusted EPS in a range of $1.72 to $1.78 per diluted share.

Additionally, for the year ending November 30, 2016, IHS Markit expects:

• Depreciation expense to be approximately $115-120 million;
• Net interest expense to be approximately $115-120 million;
• Amortization expense related to acquired intangible assets to be approximately $220-225 million;
• Stock-based compensation expense to be approximately $170-180 million;
• A GAAP effective tax rate of approximately 15-16 percent;
• An adjusted effective tax rate of approximately 25-26 percent;
• Weighted average diluted shares of approximately 317 million; and
• Total outstanding shares of approximately 442 million shares at fiscal year-end.

For additional information, see the related supplemental presentation posted to our website at investor.ihs.com.

The above outlook does not give effect to any merger-related synergies, as we are targeting the middle of the fourth quarter of fiscal 2016 for the implementation of the first round of synergies and therefore expect only a nominal level of reported synergy benefit in fiscal 2016. The above outlook also assumes no further currency movements, acquisitions, divestitures, pension mark-to-market adjustments or unanticipated events. See discussion of non-GAAP financial measures at the end of this release.

As previously announced, IHS will hold a conference call to discuss this guidance on July 13, 2016, at 8:00 a.m. EDT. The conference call will be simultaneously webcast on the company’s website: investor.ihs.com.

Use of Non-GAAP Financial Measures

Non-GAAP results are presented only as a supplement to our financial statements based on U.S. generally accepted accounting principles (GAAP). Non-GAAP financial information is provided to enhance the reader’s understanding of our financial performance, but none of these non-GAAP financial measures are recognized terms under GAAP and non-GAAP measures should not be considered in isolation or as a substitute for financial measures calculated in accordance with GAAP. We are unable to present a quantitative reconciliation of the forward-looking non-GAAP financial information presented in this release without unreasonable effort because management cannot reliably predict the necessary components of such measures aside from those components described above in this release. Accordingly, investors are cautioned not to place undue reliance on this information.

We use non-GAAP measures in our operational and financial decision-making, believing that it is useful to exclude certain items in order to focus on what we deem to be a more reliable indicator of ongoing operating performance and our ability to generate cash flow from operations. As a result, internal management reports used during monthly operating reviews feature the Adjusted EBITDA, Adjusted net income, Adjusted EPS, and free cash flow metrics. We also believe that investors may find non-GAAP financial measures useful for the same reasons, although investors are cautioned that non-GAAP financial measures are not a substitute for GAAP disclosures.

Because not all companies use identical calculations, our presentation of non-GAAP financial measures may not be comparable to other similarly-titled measures of other companies. However, these measures can still be useful in evaluating our performance against our peer companies because we believe the measures provide users with valuable insight into key components of GAAP financial disclosures.

IHS, Inc. was the accounting acquirer in the merger with Markit Ltd. As a result, IHS Markit financial results for the fiscal year ending November 30, 2016 will include 12 months of results of IHS and results of Markit from and after the July 12, 2016 closing date of the merger. Accordingly, the 2016 guidance set forth in this release has been prepared to include the results of Markit only since closing of the merger.

IHS Markit Forward-Looking Statements

This communication contains “forward-looking statements” within the meaning of the federal securities laws, including Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. In this context, forward-looking statements often address expected future business and financial performance and financial condition, and often contain words such as “expect,” “anticipate,” “intend,” “plan,” “believe,” “seek,” “see,” “will,” “would,” “target,” similar expressions, and variations or negatives of these words. Forward-looking statements by their nature address matters that are, to different degrees, uncertain, such as statements about the anticipated benefits of the transaction. These and other forward-looking statements are not guarantees of future results and are subject to risks, uncertainties and assumptions that could cause actual results to differ materially from those expressed in any forward-looking statements. Important risk factors that may cause such a difference include, but are not limited to, (i) the anticipated tax treatment, unforeseen liabilities, future capital expenditures, revenues, expenses, earnings, synergies, economic performance, indebtedness, financial condition, losses, future prospects, business and management strategies for the management, expansion and growth of the combined company’s operations, (ii) the ability of IHS Markit to integrate the business successfully and to achieve anticipated synergies, risks and costs, (iii) potential litigation relating to the proposed transaction that could be instituted against IHS, Markit or their respective directors, (iv) the ability of IHS Markit to retain and hire key personnel, (v) continued availability of capital and financing and rating agency actions, (vi) legislative, regulatory and economic developments and (vii) unpredictability and severity of catastrophic events, including, but not limited to, acts of terrorism or outbreak of war or hostilities, as well as management’s response to any of the aforementioned factors. These risks, as well as other risks, are more fully discussed in IHS Markit’s filings with the US Securities and Exchange Commission. While the list of factors presented here is considered representative, no such list should be considered to be a complete statement of all potential risks and uncertainties. Unlisted factors may present significant additional obstacles to the realization of forward-looking statements. Consequences of material differences in results as compared with those anticipated in the forward-looking statements could include, among other things, business disruption, operational problems, financial loss, legal liability to third parties and similar risks, any of which could have a material adverse effect on IHS Markit’s consolidated financial condition, results of operations, credit rating or liquidity. IHS Markit does not assume any obligation to publicly provide revisions or updates to any forward-looking statements, whether as a result of new information, future developments or otherwise, should circumstances change, except as otherwise required by securities and other applicable laws.

About IHS Markit

IHS Markit (Nasdaq: INFO) is a world leader in critical information, analytics and solutions for the major industries and markets that drive economies worldwide. The company delivers next-generation information, analytics and solutions to customers in business, finance and government, improving their operational efficiency and providing deep insights that lead to well-informed, confident decisions. IHS Markit has more than 50,000 key business and government customers, including 80 percent of the Fortune Global 500 and the world’s leading financial institutions. Headquartered in London, IHS Markit is committed to sustainable, profitable growth.

IHS Markit is a registered trademark of IHS Markit Ltd. All other company and product names may be trademarks of their respective owners. © 2016 IHS Markit Ltd. All rights reserved.

$GORO Q2 #Production Over 10k Ounces #Gold, 572k Oz. #Silver

$IOTS Secures $20 Million #DebtFacility

Financing Provides Greater Financial Flexibility to Support Growth Initiatives

SUNNYVALE, Calif., July 13, 2016  — Adesto Technologies (NASDAQ:IOTS), a leading provider of application-specific, ultra-low power non-volatile memory products, today announced that it has closed on a $20 million senior secured debt facility. The new debt facility replaces the existing April 2015 debt facility.

President and CEO Narbeh Derhacobian stated, “The closing of this debt facility further fortifies our balance sheet, while also providing greater financial flexibility as we execute on our growth initiatives. We continue to make great strides toward expanding our presence in targeted vertical markets, including consumer applications where the emergence of IoT is driving a growing need for specialized, energy-efficient memory solutions.

“More specifically, this financing helps further strengthen our financial position as we continue to target high-volume opportunities with multiple Tier-one companies. It also provides access to non-dilutive capital, enabling Adesto to consider possible strategic options for further expanding our presence in the consumer space and/or adding complementary technologies or products to help drive additional growth in the future.”

About Adesto Technologies
Adesto Technologies (NASDAQ:IOTS) is a leading provider of application-specific, ultra-low power non-volatile memory products. The company has designed and built a portfolio of innovative products with intelligent features to conserve energy and enhance performance including Fusion Serial Flash, DataFlash® and products based on Conductive Bridging RAM (CBRAM®) technology. CBRAM® is a breakthrough technology platform that enables 100 times less energy consumption than today’s memory technologies without sacrificing speed and performance. Adesto is focused on delivering differentiated solutions and helping its customers usher in the era of the Internet of Things.

Company Contact:
David Viera
Director, Corporate Communications
408-419-4844
david.viera@adestotech.com 

Adesto Technologies Investor Relations:
Shelton Group
Leanne K. Sievers, Executive Vice President
P: 949-224-3874
E: sheltonir@sheltongroup.com

$EXPI #eXpRealty Launches in #NewJersey

$CUI Expands Exclusive Hardware Design Partnership for Virtual Power Systems

TUALATIN, Ore., July 12, 2016  — CUI Global, Inc. (NASDAQ: CUI), today announced that its wholly-owned subsidiary, CUI Inc, has entered into an agreement to be the exclusive third party hardware design and development provider for  Virtual Power Systems (VPS), a cutting edge Software Defined Power^® company. This agreement further expands the previously announced limited exclusivity agreement for hardware development with VPS as the companies will continue to partner in setting a new standard for an efficient power infrastructure.

“We view software as the next step in redefining the way engineers look at power supply design,” explained Matt McKenzie, President of CUI Inc. “By becoming VPS’ exclusive hardware design firm, CUI will be able to better support our valued partner as they continue to expand the reach of their industry-changing software.”

With this agreement, CUI will become VPS’ key hardware design resource for their ICE^® (Intelligent Control of Energy) solution, enabling both CUI as well as third party power vendors to leverage its design services to accelerate time to market with VPS solutions. CUI will provide hardware design support for the ICE Block component of the system that is managed through the ICE Platform, a tightly integrated suite of software developed by VPS. The ICE system brings the benefits of elastic power to data centers, doubling power, reducing costs and improving reliability through a fully automated solution. Additionally, the new agreement will seek to expand beyond data center infrastructure and enter all market segments and applications that would benefit from a complete Software Defined Power^® ecosystem.

“CUI has proven to be a key partner on the hardware side of the Software Defined Power infrastructure and has been a great match with our innovative software. This expanded agreement enables a wider array of product offerings by CUI and third party vendors  allowing for faster adoption into new markets and applications in the future,” stated Shankar Ramamurthy, CEO of Virtual Power Systems.

“We have been incredibly pleased by our partnership with VPS and this announcement further solidifies our commitment to support leading edge innovations,” said William Clough, CUI Global’s President & CEO. “Our diversified portfolio of key partnerships and technologies will further drive profitability and bring value to our shareholders as CUI expands into ever-larger markets,” concluded Clough.

About CUI Global, Inc.
Delivering Innovative Technologies for an Interconnected World . . . . .
CUI Global, Inc. is a publicly traded company dedicated to maximizing shareholder value through the acquisition and development of innovative companies, products and technologies. From Orbital Gas Systems’ advanced GasPT2 platform targeting the energy sector, to CUI Inc’s digital power platform serving the networking and telecom space, CUI Global and its subsidiaries have built a diversified portfolio of industry leading technologies that touch many markets. As a publicly traded company, shareholders are able to participate in the opportunities, revenues, and profits generated by the products, technologies, and market channels of CUI Global and its subsidiaries. But most importantly, a commitment to conduct business with a high level of integrity, respect, and philanthropic dedication allows the organization to make a difference in the lives of their customers, employees, investors and global community.

For more information please visit www.cuiglobal.com

About CUI Inc
CUI Inc is a technology company dedicated to the development, commercialization, and distribution of new, innovative electro-mechanical products.  Over the past 20 years, CUI has become a recognized name in electronic components worldwide in the areas of power, interconnect, motion control, and sound. CUI’s solid customer commitment and honest corporate message are a hallmark in the industry. CUI is a wholly owned subsidiary of CUI Global, Inc.

For more information, please visit www.cui.com.

About Virtual Power Systems Inc.

Virtual Power Systems, Inc. (VPS) is the leading software defined power® company transforming how data centers provision, manage, and utilize power capacity. It is addressing the top growth constraint to data centers – power availability. Its software called ICE (Intelligent Control of Energy) makes power an elastic resource across the data center. As a result, infrastructure utilization is improved by up to 50% within the existing power footprint, while improving visibility, availability, and avoiding new capex. .  The VPS mission is to enable data center operators to double power and server utilization, slash costs, and improve availability

For more information please visit www.virtualpowersystems.com

Important Cautions Regarding Forward Looking Statements
This document contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such statements are subject to risks and uncertainties that could cause actual results to vary materially from those projected in the forward-looking statements. The company may experience significant fluctuations in future operating results due to a number of economic, competitive, and other factors, including, among other things, our reliance on third-party manufacturers and suppliers, government agency budgetary and political constraints, new or increased competition, changes in market demand, and the performance or reliability of our products.  These factors and others could cause operating results to vary significantly from those in prior periods, and those projected in forward-looking statements. Additional information with respect to these and other factors, which could materially affect the company and its operations, are included in certain forms the company has filed with the Securities and Exchange Commission.

$MSON #SonicVac Recognized as a Top Innovation for #WoundCare in #Podiatry

FARMINGDALE, N.Y., July 12, 2016  — Misonix, Inc. (NASDAQ: MSON), an international ultrasonic surgical device company that designs, manufactures and markets innovative therapeutic ultrasonic instruments for spine surgery, neurosurgery and other surgical specialties, today announced its recently launched product, SonicVac™, has been recognized by Podiatry Today as one of the “Top 10 Innovations in Podiatry for 2016.” Podiatry Today, an award-winning publication devoted to practicing podiatric professionals, lists the SonicVac in their July edition as an innovation that can spur wounds toward healing with the unique combination of ultrasound and aspiration.

SonicVac is the latest addition to the SonicOne^® platform that combines the advantages of vacuum aspiration with the precision and power of Low Frequency Direct Contact Ultrasound (LFDCU) debridement. From data released at the 2016 Spring Diabetic Limb Salvage Conference, this combination has shown that SonicVac increased the removal of potentially infected irrigant and debris from the treatment area by 134% over ultrasound alone.

Dr. Lee Rogers, Medical Director, Amputation Prevention Centers of America, said, “SonicOne with SonicVac allows the surgeon to selectively debride from the superficial to deep tissue while containing the spread of air-transmitted infectious matter from the surgeon and the O.R. staff.  The ability that this innovative product can provide safety for the patient and the user while potentially promoting healthy tissue regeneration for chronic wounds post debridement, positions SonicOne as the standard of advanced wound care.”

“The combination of ultrasound and aspiration in the SonicVac is both innovative and important in treating patients with chronically infected wounds. Our data indicates the containment and removal of bioburden from the wound site is a significant improvement over existing debridement approaches,” said Dr. Mark S. Granick, Professor and Chief, Division of Plastic Surgery, Rutgers, New Jersey Medical School. “The Podiatry Today Innovation recognition is timely given the focus by hospitals on infection control, decreasing length of stay and healing difficult chronic wounds. The SonicVac’s unique characteristics can enable podiatrists to improve outcomes in all of these areas.”

“This recent acknowledgement by Podiatry Today validates the hard work that our team has done to develop solutions that can significantly enhance treatment and improve patient outcomes,” remarked Scott Ludecker, Misonix Senior Vice President of Global Sales and Marketing.  “We have developed a growing portfolio of innovative medical devices that address unmet clinical needs in the marketplace, both domestically and internationally.”

Michael A. McManus, Jr., President and Chief Executive Officer of Misonix, commented, “The recognition by Podiatry Today and the wide acceptance by wound experts of SonicVac further reinforces our focus in developing products that address needs in the wound space with advanced and innovative designs.  We’re honored to be recognized this year as a Top 10 innovation.”

The SonicOne O.R. System is an innovative ultrasonic surgical debridement system that allows surgeons to address the challenges chronic wounds present to them, the patient and the health-care system. SonicOne O.R. establishes a new standard in surgical wound bed preparation, an essential first step in the wound healing process.

The SonicOne with SonicVac procedure will be sold and distributed through the Misonix sales team and its distributor network in the United States and worldwide.

About Misonix
Misonix, Inc. designs, develops, manufactures and markets therapeutic ultrasonic medical devices. Misonix’s therapeutic ultrasonic platform is the basis for several innovative medical technologies. Addressing a combined market estimated to be in excess of $1.5 billion annually; Misonix’s proprietary ultrasonic medical devices are used in spine surgery, neurosurgery, orthopedic surgery, wound debridement, cosmetic surgery, laparoscopic surgery, and other surgical and medical applications.  Additional information is available on the Company’s Web site at www.misonix.com.

Safe Harbor Statement
With the exception of historical information contained in this press release, content herein may contain “forward looking statements” that are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. These statements are based on management’s current expectations and are subject to uncertainty and changes in circumstances. Investors are cautioned that forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include general economic conditions, delays and risks associated with the performance of contracts, risks associated with international sales and currency fluctuations, uncertainties as a result of research and development, acceptable results from clinical studies, including publication of results and patient/procedure data with varying levels of statistical relevancy, risks involved in introducing and marketing new products, potential acquisitions, consumer and industry acceptance, litigation and/or court proceedings, including the timing and monetary requirements of such activities, the timing of finding strategic partners and implementing such relationships, regulatory risks including approval of pending and/or contemplated 510(k) filings, the ability to achieve and maintain profitability in the Company’s business lines, and other factors discussed in the Company’s Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The Company disclaims any obligation to update its forward-looking relationships.

$PPSI Announces $7 Million Service Agreement

Service Agreement with Large National Department Store Chain Bolsters Management’s Full-Year Revenue and EBITDA Outlook

FORT LEE, N.J., July 12, 2016  — Pioneer Power Solutions, Inc. (Nasdaq: PPSI) (“Pioneer” or the “Company”), a company engaged in the manufacture, sale and service of electrical transmission, distribution and on-site power generation equipment, today announced the Company has signed a three-year service agreement with one of the largest national department store chains in the U.S. at nearly 1,000 retail locations throughout the country. Annual billings for this order are expected to be approximately $2.3 million per year.

Pioneer, through its Titan Energy Systems Inc. subsidiary, will service and maintain the backup energy systems at the retail locations. The department store chain utilizes backup power generators to ensure business continuity and customer safety in the event of a loss of power from the grid.

Nathan Mazurek, Pioneer’s Chairman and Chief Executive Officer, said, “Maintenance of emergency backup systems is mission critical for retailers. Pioneer will be an integral part of this customer’s enterprise infrastructure, ensuring power redundancy to enable the smooth continuation of operations, the safety of the retailer’s customers and the preservation of perishable inventory items in the event of a temporary power loss. Even a momentary power outage at one location could have a profound impact on a company’s financial performance, customer loyalty or brand reputation. We are pleased to have been selected to maintain power backup systems to fill this critical need.”

About Pioneer Power Solutions, Inc.

Pioneer Power Solutions, Inc. manufactures, sells and services a broad range of specialty electrical transmission, distribution and on-site power generation equipment for applications in the utility, industrial, commercial and backup power markets. The Company’s principal products and services include custom-engineered electrical transformers, low and medium voltage switchgear and engine-generator sets and controls, complemented by a national field-service organization to maintain and repair power generation assets. Pioneer is headquartered in Fort Lee, New Jersey and operates from 13 additional locations in the U.S., Canada and Mexico for manufacturing, centralized distribution, engineering, sales, service and administration. To learn more about Pioneer, please visit its website at www.pioneerpowersolutions.com.

Safe Harbor Statement:

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company’s control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) the Company has been delinquent in payment of its federal payroll tax obligations and may not be successful in its requests for the abatement of penalties and payment of past due amounts over an extended period, (ii) the Company’s ability to expand its business through strategic acquisitions, (iii) the Company’s ability to integrate acquisitions and related businesses, (iv) the fact that many of the Company’s competitors are better established and have significantly greater resources, and may subsidize their competitive offerings with other products and services, which may make it difficult for the Company to attract and retain customers, (v) the Company’s dependence on Hydro-Quebec Utility Company and Siemens Industry, Inc. for a large portion of its business, and the fact that any change in the level of orders from Hydro-Quebec Utility Company or Siemens Industry, Inc. could have a significant impact on the Company’s results of operations, (vi) the potential loss or departure of key personnel, including Nathan J. Mazurek, the Company’s Chairman, President and Chief Executive Officer, (vii) the fact that fluctuations between the U.S. dollar and the Canadian dollar will impact the Company’s results, (viii) the Company’s ability to generate internal growth, (ix) market acceptance of existing and new products, (x) the Company’s dependence on a distributor agreement with Generac Power Systems through which its Critical Power segment derives a significant portion of its revenues, (xi) operating margin risk due to competitive pricing and operating efficiencies, supply chain risk, material, labor or overhead cost increases, interest rate risk and commodity risk, (xii) restrictive loan covenants or the Company’s ability to repay or refinance debt under its credit facilities that could limit the Company’s future financing options and liquidity position and may limit the Company’s ability to grow its business, (xiii) general economic and market conditions in the electrical equipment, power generation, commercial construction, industrial production, oil and gas, marine and infrastructure industries, (xiv) the impact of geopolitical activity on the economy, changes in government regulations such as income taxes, climate control initiatives, the timing or strength of an economic recovery in the Company’s markets and the Company’s ability to access capital markets, (xv) the fact that unanticipated increases in raw material prices or disruptions in supply could increase production costs and adversely affect the Company’s profitability, (xvi) the fact that the Company’s Chairman controls a majority of the Company’s combined voting power, and may have, or may develop in the future, interests that may diverge from yours, (xvii) material weaknesses in the Company’s internal control over financial reporting that could have an adverse effect on the Company’s business and common stock price, and (xviii) the fact that future sales of large blocks of the Company’s common stock may adversely impact the Company’s stock price. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the Securities and Exchange Commission, including the Company’s Annual and Quarterly Reports on Form 10-K and Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC’s web site at www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.

Contact:
Brett Maas, Managing Partner
Hayden IR
(646) 536-7331
brett@haydenir.com

$MTSL US State Govt. Selects #MTS #TEM Suite to Manage Telecom Expenses

RA’ANANA, Israel and RIVER EDGE, New Jersey, July 12, 2016  —

MTS – Mer Telemanagement Solutions Ltd. (NASDAQ Capital Market: MTSL), a global provider of Telecommunications Expense Management (TEM), Enterprise Mobility Management (EMM) and Video Advertising solutions, announced today that it has signed a 36-month, $718,000 TEM managed services agreement with a U.S. state government.

The MTS TEM Suite solution includes Telecom Expense Management, Enterprise Mobility Management and Unified Communications Management suites, as well as a flexible managed services offering designed to manage the entire communications lifecycle, from procurement to payment. Organizations of all sizes and industries use the MTS TEM Suite to achieve significant communications cost reductions, increased workforce productivity, corporate mobile security governance, policy compliance, as well as improved decision making through increased visibility into their global communications environment.

MTS’s TEM Suite will manage this state government’s telecom expenses, vendors, contracts, invoice processing, as well as disputes, assets, call accounting, usage, allocation and chargeback, and integration into their back office systems.  TEM Suite’s dashboards, reports, and automated alerts will provide the state with the actionable insights needed for the proactive management of their communications expenses.

“We’re excited to be selected to manage this state’s telecom expenses,” said Josef Brikman, President of North America at MTS. “TEM Suite provides our government clients with an easy to use solution that reduces communication expenses, allocates and charges back costs and creates actionable insights into their entire communications environment.”

MTS’s TEM Suite also includes other communication lifecycle management capabilities, including, procurement, wireless help desk, mobile device management (MDM), BYOD (bring your own device), wireless optimization, vendor bill payment, contract negotiation, cloud services management and tenant resale and billing. The solution’s modular design and flexible managed services offering also allows organizations to outsource their entire communications lifecycle, or outsource selective processes, depending on each organization’s unique business needs.

About MTS

Mer Telemanagement Solutions Ltd. (MTS) provides video advertising solutions for online and mobile platforms and TEM and billing solutions and services.

MTS’s Vexigo (www.vexigo.com) subsidiary creates highly sophisticated video advertising solutions for online and mobile platforms, and leverages them to offer advertising optimization services to advertisers and website owners.

MTS’s telecommunications business provides innovative products and services for enterprises in the areas of telecom expense management (TEM), enterprise mobility management (EMM), mobile virtual network operators/enablers (MVNO/MVNE) and IOT/M2M enablement for mobile service providers.

Headquartered in Israel, MTS markets its solutions through wholly-owned subsidiaries in Israel, the U.S and Hong Kong, as well as through distribution channels. For more information, please visit the MTS web site: www.mtsint.com.

Certain matters discussed in this news release are forward-looking statements that involve a number of risks and uncertainties including, but not limited to, risks in product development plans and schedules, rapid technological change, changes and delays in product approval and introduction, customer acceptance of new products, the impact of competitive products and pricing, market acceptance, the lengthy sales cycle, proprietary rights of the Company and its competitors, risk of operations in Israel, government regulations, dependence on third parties to manufacture products, general economic conditions and other risk factors detailed in the Company‘s filings with the United States Securities and Exchange Commission.

Company Contacts:
MTS Contact:
John Venditti
Vice President, Marketing
+1(800)745-8725
john.venditti@mtsint.com